Review



cd59 antibody  (NSJ Bioreagents)


Bioz Verified Symbol NSJ Bioreagents is a verified supplier
Bioz Manufacturer Symbol NSJ Bioreagents manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    NSJ Bioreagents cd59 antibody
    Cd59 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 263 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd59 antibody/product/NSJ Bioreagents
    Average 99 stars, based on 263 article reviews
    cd59 antibody - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    cd59 antibody  (NSJ Bioreagents)
    99
    NSJ Bioreagents cd59 antibody
    Cd59 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd59 antibody/product/NSJ Bioreagents
    Average 99 stars, based on 1 article reviews
    cd59 antibody - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    catalog 12474 r029 a  (Sino Biological)
    94
    Sino Biological catalog 12474 r029 a
    Catalog 12474 R029 A, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/catalog 12474 r029 a/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    catalog 12474 r029 a - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    anti cd59 apc  (Sino Biological)
    94
    Sino Biological anti cd59 apc
    Anti Cd59 Apc, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd59 apc/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    anti cd59 apc - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    anti human cd59 fitc  (Miltenyi Biotec)
    93
    Miltenyi Biotec anti human cd59 fitc
    Gene expression and cytogenetic clusters in MM. (A) Violin plots showing gene expression levels for TNFRSF13B , <t>CD59</t> , FCGR2B , SLC44A1 , and CD320 in HD, MGUS, SMM, MM, RRMM. Statistical comparisons were conducted using the Kruskal–Wallis test for all pairwise contrasts. (B) Heatmap of the pseudobulk expression profiles showing normalized expression levels for eight putative proxy markers of cytogenetic aberrations across 54 MM patients. (C) Box plots illustrating the differential expression of TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 across the four cytogenetic patient clusters. Statistical significance was evaluated using two-sided t -tests for all pairwise comparisons p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).
    Anti Human Cd59 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human cd59 fitc/product/Miltenyi Biotec
    Average 93 stars, based on 1 article reviews
    anti human cd59 fitc - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    cd59  (Proteintech)
    94
    Proteintech cd59
    Gene expression and cytogenetic clusters in MM. (A) Violin plots showing gene expression levels for TNFRSF13B , <t>CD59</t> , FCGR2B , SLC44A1 , and CD320 in HD, MGUS, SMM, MM, RRMM. Statistical comparisons were conducted using the Kruskal–Wallis test for all pairwise contrasts. (B) Heatmap of the pseudobulk expression profiles showing normalized expression levels for eight putative proxy markers of cytogenetic aberrations across 54 MM patients. (C) Box plots illustrating the differential expression of TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 across the four cytogenetic patient clusters. Statistical significance was evaluated using two-sided t -tests for all pairwise comparisons p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).
    Cd59, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd59/product/Proteintech
    Average 94 stars, based on 1 article reviews
    cd59 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    cd59a  (Miltenyi Biotec)
    93
    Miltenyi Biotec cd59a
    Gene expression and cytogenetic clusters in MM. (A) Violin plots showing gene expression levels for TNFRSF13B , <t>CD59</t> , FCGR2B , SLC44A1 , and CD320 in HD, MGUS, SMM, MM, RRMM. Statistical comparisons were conducted using the Kruskal–Wallis test for all pairwise contrasts. (B) Heatmap of the pseudobulk expression profiles showing normalized expression levels for eight putative proxy markers of cytogenetic aberrations across 54 MM patients. (C) Box plots illustrating the differential expression of TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 across the four cytogenetic patient clusters. Statistical significance was evaluated using two-sided t -tests for all pairwise comparisons p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).
    Cd59a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd59a/product/Miltenyi Biotec
    Average 93 stars, based on 1 article reviews
    cd59a - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    cd59 antibody  (Proteintech)
    94
    Proteintech cd59 antibody
    Cellular response and cholesterol modulation by Fe/CDP. ( a ) Histogram depicting cellular uptake efficiency. ( b ) Comparative evaluation of CS-mediated targeting capacities across different cell lines. ( c-e ) Dose-dependent cytotoxicity profiles of 4T1 cells treated with Fe/C ( c ), pravastatin (d), and DOX ( e ) ( n = 3). ( f ) Cell viability of 4T1 cells treated with indicated treatments. ( g , h ) Fluorescent images of intracellular cholesterol distribution ( g ) and corresponding quantitative analysis ( n = 3) ( h ). ( i ) Membrane fluidity assessment ( n = 3). ( j-l ) Schematic representation ( j ), microscopic visualization ( k ), and quantitative analysis ( l ) of cell adhesion assay ( n = 3). ( m) Western blot analysis of HMGCR, E-cadherin, and <t>CD59</t> protein expression levels. ( n ) Proposed mechanism of cholesterol depletion in modulating membrane rigidity and fluidity. Statistical significance denoted as * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns: not significant ( p > 0.05), analyzed by one-way ANOVA, followed by Dunnett’s multiple comparisons test. Data represent mean ± standard deviation (s.d.)
    Cd59 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd59 antibody/product/Proteintech
    Average 94 stars, based on 1 article reviews
    cd59 antibody - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Gene expression and cytogenetic clusters in MM. (A) Violin plots showing gene expression levels for TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 in HD, MGUS, SMM, MM, RRMM. Statistical comparisons were conducted using the Kruskal–Wallis test for all pairwise contrasts. (B) Heatmap of the pseudobulk expression profiles showing normalized expression levels for eight putative proxy markers of cytogenetic aberrations across 54 MM patients. (C) Box plots illustrating the differential expression of TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 across the four cytogenetic patient clusters. Statistical significance was evaluated using two-sided t -tests for all pairwise comparisons p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).

    Journal: Frontiers in Medicine

    Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

    doi: 10.3389/fmed.2025.1737919

    Figure Lengend Snippet: Gene expression and cytogenetic clusters in MM. (A) Violin plots showing gene expression levels for TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 in HD, MGUS, SMM, MM, RRMM. Statistical comparisons were conducted using the Kruskal–Wallis test for all pairwise contrasts. (B) Heatmap of the pseudobulk expression profiles showing normalized expression levels for eight putative proxy markers of cytogenetic aberrations across 54 MM patients. (C) Box plots illustrating the differential expression of TNFRSF13B , CD59 , FCGR2B , SLC44A1 , and CD320 across the four cytogenetic patient clusters. Statistical significance was evaluated using two-sided t -tests for all pairwise comparisons p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).

    Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

    Techniques: Gene Expression, Expressing, Quantitative Proteomics

    Kaplan–Meier survival curves showing the prognostic relevance of mRNA expression levels for CD59, SLC44A1, FCGR2B, TNFRSF13B, and CD320 genes. Cell populations with high expression of each gene are shown in blue, while populations with low expression of the same mRNA are shown in red. Reference datasets (GSE, GEO Series) are indicated at the top of each panel. Prognostic significance was assessed using the Cox proportional hazards model (95% confidence interval CI) and log-rank test, with p < 0.05 considered statistically significant.

    Journal: Frontiers in Medicine

    Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

    doi: 10.3389/fmed.2025.1737919

    Figure Lengend Snippet: Kaplan–Meier survival curves showing the prognostic relevance of mRNA expression levels for CD59, SLC44A1, FCGR2B, TNFRSF13B, and CD320 genes. Cell populations with high expression of each gene are shown in blue, while populations with low expression of the same mRNA are shown in red. Reference datasets (GSE, GEO Series) are indicated at the top of each panel. Prognostic significance was assessed using the Cox proportional hazards model (95% confidence interval CI) and log-rank test, with p < 0.05 considered statistically significant.

    Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

    Techniques: Expressing

    Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on different MM cell lines, including AMO-1, OPM-2, RPMI8226, U-266, and H929 as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker, allowing comparison of protein abundance across the different cell lines compared to unstained control (in blue).

    Journal: Frontiers in Medicine

    Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

    doi: 10.3389/fmed.2025.1737919

    Figure Lengend Snippet: Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on different MM cell lines, including AMO-1, OPM-2, RPMI8226, U-266, and H929 as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker, allowing comparison of protein abundance across the different cell lines compared to unstained control (in blue).

    Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

    Techniques: Expressing, Flow Cytometry, Marker, Comparison, Quantitative Proteomics, Control

    Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on malignant plasma cells (PCs) from eight bone marrow samples of newly diagnosed, untreated MM patients as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker across the eight MM patients samples, allowing comparison of protein abundance compared to unstained control (in blue).

    Journal: Frontiers in Medicine

    Article Title: Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma

    doi: 10.3389/fmed.2025.1737919

    Figure Lengend Snippet: Histogram plots showing the cell surface expression of CD59, CD92, CD267, and CD320 molecules on malignant plasma cells (PCs) from eight bone marrow samples of newly diagnosed, untreated MM patients as measured by flow cytometry analysis using fluorochrome-conjugated antibodies in triplicate experiments. Each panel represents the distribution of expression levels for the indicated marker across the eight MM patients samples, allowing comparison of protein abundance compared to unstained control (in blue).

    Article Snippet: Antibodies included: anti-human CD45 V500 (HI30), anti-human CD19 APC-H7 (HIB19), anti-human CD59 FITC (H19), anti-human CD92 BV605 (VIM15), anti-human CD267 BV421 (1A1-K21-M22) (all from BD Biosciences, USA), anti-human CD38 PE (REA572, Miltenyi Biotec, Germany), and anti-human CD320 AlexaFluor 647 (Antibodies Online, Germany).

    Techniques: Expressing, Clinical Proteomics, Flow Cytometry, Marker, Comparison, Quantitative Proteomics, Control

    Cellular response and cholesterol modulation by Fe/CDP. ( a ) Histogram depicting cellular uptake efficiency. ( b ) Comparative evaluation of CS-mediated targeting capacities across different cell lines. ( c-e ) Dose-dependent cytotoxicity profiles of 4T1 cells treated with Fe/C ( c ), pravastatin (d), and DOX ( e ) ( n = 3). ( f ) Cell viability of 4T1 cells treated with indicated treatments. ( g , h ) Fluorescent images of intracellular cholesterol distribution ( g ) and corresponding quantitative analysis ( n = 3) ( h ). ( i ) Membrane fluidity assessment ( n = 3). ( j-l ) Schematic representation ( j ), microscopic visualization ( k ), and quantitative analysis ( l ) of cell adhesion assay ( n = 3). ( m) Western blot analysis of HMGCR, E-cadherin, and CD59 protein expression levels. ( n ) Proposed mechanism of cholesterol depletion in modulating membrane rigidity and fluidity. Statistical significance denoted as * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns: not significant ( p > 0.05), analyzed by one-way ANOVA, followed by Dunnett’s multiple comparisons test. Data represent mean ± standard deviation (s.d.)

    Journal: Journal of Nanobiotechnology

    Article Title: Targeting cancer stem-like cells via cholesterol modulation and ferroptosis induction using a multifunctional nanoplatform to overcome drug resistance

    doi: 10.1186/s12951-025-03796-y

    Figure Lengend Snippet: Cellular response and cholesterol modulation by Fe/CDP. ( a ) Histogram depicting cellular uptake efficiency. ( b ) Comparative evaluation of CS-mediated targeting capacities across different cell lines. ( c-e ) Dose-dependent cytotoxicity profiles of 4T1 cells treated with Fe/C ( c ), pravastatin (d), and DOX ( e ) ( n = 3). ( f ) Cell viability of 4T1 cells treated with indicated treatments. ( g , h ) Fluorescent images of intracellular cholesterol distribution ( g ) and corresponding quantitative analysis ( n = 3) ( h ). ( i ) Membrane fluidity assessment ( n = 3). ( j-l ) Schematic representation ( j ), microscopic visualization ( k ), and quantitative analysis ( l ) of cell adhesion assay ( n = 3). ( m) Western blot analysis of HMGCR, E-cadherin, and CD59 protein expression levels. ( n ) Proposed mechanism of cholesterol depletion in modulating membrane rigidity and fluidity. Statistical significance denoted as * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns: not significant ( p > 0.05), analyzed by one-way ANOVA, followed by Dunnett’s multiple comparisons test. Data represent mean ± standard deviation (s.d.)

    Article Snippet: GPX4 antibody (Cat#67763-1-Ig), γ-H 2 AX antibody (Cat#10856-1-AP), β-actin antibody (Cat#66009-1-Ig), P glycoprotein antibody(Cat#22336-1-AP), HMGCR antibody (Cat#13533-1-AP), EGFR antibody (Cat#18986-1-AP), CD59 antibody (Cat#10742-1-AP), FSP1 antibody (Cat# 20886-1-AP), HRP-conjugated Goat Anti-Mouse IgG(H + L) (Cat#SA00001-1), HRP-conjugated Goat Anti-Rabbit IgG(H + L) (Cat#SA00001-2) were gained from Proteintech.

    Techniques: Membrane, Cell Adhesion Assay, Western Blot, Expressing, Standard Deviation